Does evidence matter? Comparative effectiveness research and prescribing of Type 2 diabetes mellitus drugs.
Conclusion: CER evidence appeared to be associated with prescribing trends in GLP-1 agonists market; however, no associations were found in DPP4 inhibitors market. The translation of evidence into practice can be limited by the availability of superiority trials and timing of their availability. PMID: 31789054 [PubMed - as supplied by publisher]
ConclusionDisease cost analyses in hospitals are required in order to prioritize healthcare services, use resources efficiently and decrease the financial burden of diseases on the society.
Type 2 diabetes mellitus (T2DM) is one of the most prevalent endocrine diseases in the world. Recent studies have shown that dysbiosis of the gut microbiota may be an important contributor to T2DM pathogenesis. However, the mechanisms underlying the roles of the gut microbiome and fecal metabolome in T2DM have not been characterized. Recently, the Goto-Kakizaki (GK) rat model of T2DM was developed to study the clinical symptoms and characteristics of human T2DM. To further characterize T2DM pathogenesis, we combined multi-omics techniques, including 16S rRNA gene sequencing, metagenomic sequencing, and metabolomics, to ana...
This study aimed to design a simple surrogate marker (i.e., predictor) of the minimal model glucose effectiveness (SG), namely calculated SG (CSG), from a short insulin-modified intravenous glucose tolerance test (IM-IVGTT), and then to apply it to study women with previous gestational diabetes mellitus (pGDM). METHODS: CSG was designed using the stepwise model selection approach on a population of subjects (n=181) ranging from normal tolerance to type 2 diabetes mellitus (T2DM). CSG was then tested on a population of women with pGDM (n=57). Each subject underwent a 3-hour IM-IVGTT; women with pGDM were observed early ...
We reported a significant increase of ghrelin epsilon-cells in the pancreas and basal serum after Sleeve gastrectomy versus the control groups. The epsilon cellular increment was related to neogenesis, as the neurogenin-3 marker revealed. The Roux-en Y Gastric Bypass showed neither epsilon cell increase nor basal serum changes in ghrelin release. As a conclusion, we reported that the severe suppression of the fundus gastric produced the recovery of ghrelin released by the epsilon cells, which was indicative of an ontogenic embryonic pancreatic function. PMID: 31951010 [PubMed - as supplied by publisher]
Indigenous populations worldwide have a high prevalence of type 2 diabetes mellitus (T2D), and early age of onset. The causes of increased rates of T2D are likely multiple and complex. However, social determinants of health appear to be associated with differences in prevalence across populations, including in youth. The prevalence of T2D is directly related to the prevalence of obesity which is also influenced by social determinants of health. Understanding the relationship between social determinants of health and neonatal adiposity may inform early life interventions to improve metabolic health.
AbstractPurpose of ReviewType 2 diabetes (T2DM) presents a growing global health and economic burden. Dental settings have been employed to identify individuals who may be at high risk of diabetes, who exhibit non-diabetic hyperglycaemia (NDH – also termed “prediabetes”) and who already unknowingly have the condition, through the use of targeted risk-assessments. This review aims to synthesize the existing literature supporting dental teams’ identification of individuals at an increased risk of or suffering from undiagnosed NDH o r T2DM in dental specialist care settings.Recent FindingsElectronic da...
CONCLUSION: It is very important for public health that the current EU standards for rkedly lowered so that health risks can be further reduced, in accordance with the recommendations of the WHO. PMID: 31941576 [PubMed - in process]
Condition: Diabetes Mellitus, Type 2 Intervention: Drug: Cynara Scolymus Sponsor: Stefan Fischli Not yet recruiting
Condition: Type 2 Diabetes Mellitus With Circulatory Complciation Intervention: Device: The Neurotronic arterial ablation catheter Sponsors: Neurotronic, Inc.; Libra Medical Recruiting